The Lancet

Endothelin antagonism in IgA nephropathy: promise ahead of proof?

Endothelin biology remains an attractive therapeutic target in IgA nephropathy where intrarenal endothelin-1 expression is upregulated and implicated in nephron loss through vasoconstriction, ...

IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight

IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight The IgE receptor antagonists clinical trial ...
TMCnet

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Title: First-in-human study demonstrates GIP-Receptor (GIPR) antagonist, AT7687, as well-tolerated and suitable for once-weekly subcutaneous injection for treatment in people living with obesity Date: ...
The Manila Times

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial ...
EurekAlert!

Neurokinin-1 receptor antagonists in the current management of chemotherapy-induced nausea and vomiting

Chemotherapy-induced nausea and vomiting (CINV) represents one of the most distressing and debilitating side effects experienced by cancer patients undergoing treatment, significantly impacting ...
Medical News Today

What to know about opioid antagonists

Opioid antagonists are medications people can take to treat opioid use disorder. They help by reducing withdrawal symptoms, addressing cravings, and managing overdoses. Doctors prescribe opioid ...